Retrospective clinical studies of patients with melanoma, thyroid cancer, and breast cancer have found that prophylactic lymph node removal does not improve survival, and the research featured in Xue et al. [107] has shown that surgical removal of TDLNs before tumor implantation and/or anti-PD-1 therapy could reduce treatment efficacy. This evidence concerns the gene PDCD1 and melanoma.